For the second time in as many days, Merck has reported a Phase III failure for its blockbuster PD-1 inhibitor Keytruda, this time as a first-line treatment with Eisai’s Lenvima for cancer in the uterus lining.
The company stated that its cancer drug Jemperli when combined with chemotherapy, met the primary goal of overall survival in patients with advanced or recurrent endometrial cancer in a late-stage trial.
The FDA has approved Jemperli as an add-on to chemotherapy for patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient or microsatellite instability-high.
The company made the announcement this morning.
Today AstraZeneca announced that a combination of its cancer drugs Imfinzi and Lynparza when added to platinum-based chemotherapy showed positive results in a late-stage trial in patients with advanced or recurrent endometrial cancer.
Merck’s Keytruda appeared to outperform GSK’s Jemperli in a key endometrial cancer patient subgroup, suggesting late-stage data revealed Monday during the Society of Gynecologic Oncology 2023 Annual Meeting.
Blueprint Medicines Corp. said on Friday the U.S. drug regulator had put on partial hold an early-stage trial testing its experimental cancer drug due to safety concerns, sending its shares down nearly 6%.
It was a good Thursday for GSK’s Jemperli (dostarlimab), as the immunotherapy received both full FDA approval in endometrial cancer and the regulatory go-ahead regarding its development plan in rectal cancer.
Keytruda, could be on its way to snagging another indication as a first-line therapy for endometrial cancer after the company announced positive Phase III results Friday.
The buyout will grant Leap Therapeutics access to Flame Bioscience’s portfolio, which includes a clinical-stage monoclonal antibody that is under investigation as a potential treatment for gastric, gastroesophageal junction, and pancreatic cancers.